921630-61-7

Upstream product

• 877995-77-2 1-(4-bromophenoxy)-2-(2,6-dichloro-4-methylphenoxy)ethane 
• 201230-82-2 carbon monoxide 
• 2432-12-4 2,6-dichloro-4-methylophenol 
• 68-12-2 N,N-dimethyl-formamide 
• 921630-64-0 2-(2,6-dichloro-4-methyl-phenoxy)-ethanol 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 1251530-37-6 C₂₀H₂₀Cl₂O₄ 
• 1026192-65-3 sodium 2-{[3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropanecarboxylate 
• 1056555-28-2 ethyl 2-(((3-(((3-(tert-butoxycarbonyl)amino)-2-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)benzyl)propanoyl)(cyclopropyl)amino)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylate 
• 1056555-23-7 tert-butyl (3-[(cyclopropyl)[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 1056555-32-8 tert-butyl (3-(cyclopropyl((2-(3-methoxypropyl)-6-(3-(methylsulfonyl)propoxy)-1-oxidopyridin-4-yl)methyl)amino)-2-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)benzyl)-3-oxopropyl)carbamate 
• 1056555-25-9 tert-butyl (3-[(cyclopropyl)[3-(3-methoxypropyl)-5-[3-(methylsulfonyl)propoxy]benzyl]amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 1056555-30-6 tert-butyl (3-(cyclopropyl((2-(3-methoxypropyl)-6-(3-(methylsulfonyl)propoxy)pyridin-4-yl)methyl)amino)-2-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)benzyl)-3-oxopropyl)carbamate 
• 1056555-22-6 tert-butyl (3-[[3-{[tert-butyl(dimethyl)silyl]oxy}-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 1056555-31-7 tert-butyl (3-[{[2-{[tert-butyl(dimethyl)silyl]oxy}-6-(3-methoxypropyl)pyridin-4-yl]methyl}(cyclopropyl)amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 1056555-26-0 tert-butyl (3-{cyclopropyl[3-(3-methoxypropyl)-5-(2-pyridin-2-ylethoxy)benzyl]amino}-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 1056555-24-8 tert-butyl (3-[(cyclopropyl)[3-(3-methoxypropyl)-5-[3-(methylthio)propoxy]benzyl]amino]-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-3-oxopropyl)carbamate 
• 921629-96-1 3-{[(3-amino-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}propanoyl)(cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenyl (3-amino-2,2-dimethyl-3-oxopropyl)carbamate 
• 921629-56-3 3-amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-[3-(3-methoxypropyl)-5-(2-pyrrolidin-1-ylethoxy)benzyl]propanamide 
• 921629-90-5 3-amino-N-cyclopropyl-2-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]benzyl}-N-({2-(3-methoxypropyl)-6-[3-(methylsulfonyl)propoxy]-1-oxidopyridin-4-yl}methyl)propanamide 

Relevant academic research and scientific papers

Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study

Time-dependent inhibitors of CYPs have the potential to perpetrate drug-drug interactions in the clinical setting. After finding that several leading compounds in a novel series of substituted amino propanamide renin inhibitors inactivated CYP3A4 in an NA

RENIN INHIBITORS

The present invention relates to biphenyl compounds of formula (I). These compounds are renin inhibitors of a non- peptidic nature and of low molecular weight. The invention further relates to a pharmaceutical composition containing said compounds, as wel

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

RENIN INHIBITORS

The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.